Impact of concurrent macrovascular co-morbidities on healthcare utilization in patients with type 2 diabetes in Europe: A matched study

Diabetes, Obesity and Metabolism

Volumn 12, Issue 7, 2010, Pages 631-637

  Fu, A Z ^a   Qiu, Y ^b   Radican, L ^b   Yin, D D ^b   Mavros, P ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Europe; Healthcare utilization; Macrovascular disease; Type 2 diabetes

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; GLITAZONE DERIVATIVE; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; SULFONYLUREA;

ADULT; ARTICLE; COMORBIDITY; CONTROLLED STUDY; EMERGENCY CARE; EUROPE; FEMALE; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; MACROVASCULAR COMORBIDITY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; SURGICAL TECHNIQUE; VASCULAR DISEASE;

EID: 77954181415     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2010.01200.x     Document Type: Article

References (22)

1. Diabetes Programme Fact sheet, September. 2006, http://www.who.int/mediacentre/factsheets/fs312/en/index.html, World Health Organization, Available at:, (accessed 13 October 2008).
2. http://www.heartstats.org/datapage.asp?id=4529, Diabetes in Europe, Available at:, (accessed: 23 April 2009).
3. Prevalence and Incidence 2004, Centers for Disease Control and Prevention, 1999 Diabetes Surveillance Report., Atlanta, GA, U.S. Department of Health and Human Services
4. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229-234.
5. Glauber H, Brown J. Impact of cardiovascular disease on health care utilization in a defined diabetic population. J Clin Epidemiol 1994, 47:1133-1142.
6. Gandra SR, Lawrence LW, Parasuraman BM, Darin RM, Sherman JJ, Wall JL. Total and component health care costs in a non-Medicare HMO population of patients with and without type 2 diabetes and with and without macrovascular disease. J Manag Care Pharm 2006, 12:546-554.
7. Gilmer TP, O'Connor PJ, Rush WA. Predictors of health care costs in adults with diabetes. Diabetes Care 2005, 28:59-64.
8. Nichols GA, Brown JB. The impact of cardiovascular disease on medical care costs in subjects with and without type 2 diabetes. Diabetes Care 2002, 25:482-486.
9. Clarke P, Gray A, Legood R, Briggs A, Holman R. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabet Med 2003, 20:442-450.
10. Currie CJ, Morgan CL, Peters JR. Patterns and costs of hospital care for coronary heart disease related and not related to diabetes. Heart 1997, 78:544-549.
11. Colin X, Lafuma A, Gueron B. Costs of cardiovascular events of diabetic patients in the French hospitals. Diabetes & Metabolism 2007, 33:310-313.
12. Alvarez Guisasola F, Mavros P, Nocea G, Alemao E, Alexander CM, Yin D. Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study. Diabetes Obes Metab 2008, 10(Suppl. 1):8-15.
13. Alvarez Guisasola F, Tofé Povedano S, Krishnarajah G, Lyu R, Mavros P, Yin D. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study. Diabetes Obes Metab 2008, 10(Suppl. 1):25-32.
14. Diagnosis and classification of diabetes mellitus: clinical practice recommendations. Diabetes Care 2007, (Suppl. 1):S42-S47. American Diabetes Association, (
15. Clarke PM, Gray AM, Briggs A. A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 2004, 47:1747-1759.
16. Fu AZ, Li L. Thinking of having a higher predictive power for your first-stage model in propensity score analysis? Think again. Health Serv Outcomes Res Method 2008, 8:115-117.
17. Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Sturmer T. Variable selection for propensity score models. Am J Epidemiol 2006, 163:1149-1156.
18. Parsons LS. 2004, Performing a 1:N case-control match on propensity score. Proceedings of the 29th SAS Users Group International (SUGI) Conference,, paper 165-29, Montreal, Quebec, Canada.
19. O'Brien JA, Shomphe LA, Kavanagh PL, Raggio G, Caro JJ. Direct medical costs of complications resulting from type 2 diabetes in the U.S. Diabetes Care 1998, 21:1122-1128.
20. Selby JV, Ray GT, Zhang D, Dolby CJ. Excess costs of medical care for patients with diabetes in a managed care population. Diabetes Care 1997, 20:1396-1402.
21. Fu AZ, Qiu Y, Radican L, Wells BJ. Healthcare and productivity costs associated with diabetic patients with macrovascular comorbid conditions. Diabetes Care 2009, 32:2187-2192.
22. Fu AZ, Dow WH, Liu GG. Propensity score and difference-in-difference methods: a study of second-generation antidepressant use in patients with bipolar disorder. Health Serv Outcomes Res Method 2007, 7:23-38.